microfluidics

Namocell has partnered with the two firms to distribute its cell dispensing tool in South Korea, the Netherlands, Belgium, and Luxembourg.

The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.

The firm will use the net proceeds to advance commercialization of its microfluidic technology and for general corporate purposes.

Tomy Digital Biology has agreed to distribute Namocell's microfluidic-based cell platforms in the Japanese market.

The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.

The Alameda, California-based startup will use the funding to advance the commercialization of its rapid diagnostic platform for infectious diseases.

The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.